Aisner J, Alberto P, Bitran J, Comis R, Daniels J, Hansen H, Ikegami H, Smyth J
Cancer Treat Rep. 1983 Jan;67(1):37-43.
Many studies in small cell carcinoma of the lung (SCCL) have demonstrated a high response rate and a potential for cure in a subset of patients. Combination chemotherapy, the cornerstone of all treatment for SCCL, can produce up to 10% long-term, disease-free survival among all patients with SCCL and greater than or equal to 20% survival among patients who present with limited disease. Significant improvements in survival have occurred in all stages of disease, and further investigative efforts are necessary to improve the complete remission rate, the duration of response, and the percentage of long-term, disease-free survivors. The current report, based on the workshop on SCCL held in Ireland under the auspices of the International Association for the Study of Lung Cancer, reviews the current state of the art for chemotherapy and presents potential future directions.
许多关于肺小细胞癌（SCCL）的研究表明，一部分患者有较高的缓解率和治愈潜力。联合化疗是SCCL所有治疗方法的基石，在所有SCCL患者中可产生高达10%的长期无病生存率，在疾病局限的患者中生存率大于或等于20%。疾病各阶段的生存率均有显著提高，还需要进一步的研究努力来提高完全缓解率、缓解持续时间以及长期无病生存者的比例。本报告基于在国际肺癌研究协会主持下于爱尔兰举办的SCCL研讨会，回顾了化疗的当前技术水平，并提出了未来可能的发展方向。
